The study was not powered for comparison between different PTCL subtypes, but in an intention-to-treat population, ALK+ ALCL appeared to benefit the most with the lowest hazard ratio point estimate. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.